Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012

Orexigen® Therapeutics, Inc. (OREX) today announced an update to the projected timeframe for enrollment of patients in the Light Study, the cardiovascular outcomes clinical trial evaluating Contrave® (naltrexone SR/ bupropion SR).  Enrollment into the study has continued without abatement at a rate faster than originally expected, with more than 4,500 patients enrolled as of August 31.  Orexigen now expects to close enrollment to new patients in the fourth quarter of 2012.

The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo.

Repros Announces the Offering of Unregistered Shares of Common Stock in the Amount of $23.6 Million

Repros Therapeutics Inc.^(R) (RPRX) announced today that it entered into a purchase agreement with several institutional investors to sell an aggregate of 2,145,636 shares of common stock at $11 per share, in a private placement for gross proceeds of approximately $23.6 million, before deducting offering expenses. The proceeds will be used to fund the Company's Androxal(R) and Proellex(R) programs. Closing is expected to occur later this week.